Black Diamond Therapeutics Inc. Stock News

CAMBRIDGE, Mass. and NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of Mas

CAMBRIDGE, Mass. and NEW YORK, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of Mast

CAMBRIDGE, Mass. and NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of Mast

CAMBRIDGE, Mass. and NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of Maste

US crude oil futures traded lower on Monday. Investors, meanwhile, focused on some notable insider trades.

CAMBRIDGE, Mass. and NEW YORK, April 07, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of Mas

Black Diamond Therapeutics Inc (BDTX) shares closed 0.5% lower than its previous 52 week low, giving the company a market cap of $163M. The stock is currently down 15.4% year-to-date, down 84.8% over the past 12 months, and down 88.6% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 17.5% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 408.8% The company's stock price performance over the past 12 months lags the peer average by 177.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Black Diamond Therapeutics Inc (BDTX) shares closed today 11.6% lower than it did at the end of yesterday. The stock is currently down 4.3% year-to-date, down 85.3% over the past 12 months, and down 87.1% over the past five years. Today, the Dow Jones Industrial Average rose 0.1%, and the S&P 500 rose 0.3%. Trading Activity Shares traded as high as $5.21 and as low as $4.32 this week.Shares closed 85.3% below its 52-week high and 4.4% above its 52-week low.Trading volume this week was 539.8% higher than the 10-day average and 1417.2% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -814.0% The company's stock price performance over the past 12 months lags the peer average by 197.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Are these penny stocks worth buying in 2022? The post Hot Penny Stocks to Add to Your Mid-January Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Black Diamond Therapeutics (BDTX) has added ~21.8% in the pre-market on above-average volume after announcing that the FDA cleared its investigational new drug ((IND)) application

CAMBRIDGE, Mass. and NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of Mast

Cardiff Oncology (NASDAQ:CRDF) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends and risk. Profitability This table compares Cardiff Oncology and Black Diamond Therapeutics net margins, return on []

Morgan Stanley increased its stake in shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) by 4,599.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 601,020 shares of the companys stock after acquiring an additional 588,232 shares during the quarter. Morgan []

Goldman Sachs Group Inc. boosted its stake in shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) by 128.9% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 193,462 shares of the companys stock after acquiring an additional 108,934 shares during the period. []

CAMBRIDGE, Mass. and NEW YORK, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of Mast